Clinical Trials Browser

Terminated × Neoplasm Metastasis × osimertinib × Clear all

NCT03255083 2022-01-19

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1 Terminated

13 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms